Full-Time

Forensic Scientist Industrial Placement

Posted on 9/27/2025

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Canterbury, UK

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Must be registered on an undergraduate forensic sciences related degree program, must have completed at least 2 years of study and must not have graduated at the start of the placement.
  • Must be familiar with the basic principles of analytical chemistry
  • Must possess good IT skills (Microsoft Excel, Word, and PowerPoint)
  • Must be able to work collaboratively within a team environment
  • Must be able to organise tasks allocated by supervisor and plan own work to consistently achieve output of high-quality results in a timely manner, following established analytical methods and operating procedures.
  • Must have enthusiasm to work in a lab-based role
  • Must have good written and oral communication
Responsibilities
  • Carry out analytical activities required to deliver forensic review of suspect illicit goods.
  • Execute experiments to generate scientific understanding in development of forensic methods and processes.
  • Perform analyses related to authentic and suspect illicit samples.
  • Process data: highlight aberrant or suspect results and work with supervisor to investigate.
  • Maintain laboratory documentation in accordance with good documentation practices.
  • Maintain and troubleshoot instrumentation.
  • Contribute to project delivery by carrying out other tasks (e.g., laboratory housekeeping, ordering, shipping samples) as required.
Desired Qualifications
  • Has knowledge and/or experience of modern instrumental methods of analysis, e.g., FT-IR, Raman and GC-MS techniques.
  • Experience or knowledge in photography of evidence.
  • Experience or knowledge of handing evidence and maintaining Chain of Custody.
  • Good understanding of laboratory safety and best practice.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Greater China and emerging markets drove Q1 2026 growth.
  • Six 2026 regulatory decisions can unlock multiple launches.
  • $650 million cost savings and $2.5 billion deployable cash support returns.

What critics are saying

  • North American generic pricing pressure keeps compressing core developed-market revenue.
  • Launch-dependent guidance fails if MR-107A-02 or MR-141 slips.
  • China concentration exposes growth to policy and channel disruptions.

What makes Viatris unique

  • Formed in November 2020 from Mylan and Upjohn.
  • Operates across more than 165 countries with 1,400 therapeutic molecules.
  • Combines branded, generic, complex, biosimilar, and OTC medicines.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Viatris who can refer or advise you

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-6%

2 year growth

-6%
Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.

INACTIVE